Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Data Brief
Autors principals: Faehling, Martin, Schumann, Christian, Christopoulos, Petros, Hoffknecht, Petra, Alt, Jürgen, Horn, Marlitt, Eisenmann, Stephan, Schlenska-Lange, Anke, Schütt, Philipp, Steger, Felix, Brückl, Wolfgang M., Christoph, Daniel C.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Data Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7750486/
https://ncbi.nlm.nih.gov/pubmed/33364266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2020.106556
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars